Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Clinical
  3. /Readouts

Clinical

Readouts(50)

Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.

50 signals

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ScoreIntelligence Record
8.0

CLINICAL

Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise

A study is investigating the use of banked virus-specific T cells (VSTs) to treat persistent viral infections after allogeneic stem cell transplants.

Tetravi·August 2, 2026
8.0

CLINICAL

CAFs Enhance Adenosine Production in NSCLC, Impeding T Cell Response

Cancer-associated fibroblasts (CAFs) promote the expression of CD39 and CD73 on T cells, leading to increased adenosine synthesis, which may facilitate tumor immune evasion.

August 1, 2026
8.0

CLINICAL

Platelet-based delivery of fluorescein enhances sonodynamic therapy in glioblastoma

A novel platelet-based delivery system for fluorescein significantly enhances the efficacy of sonodynamic therapy in glioblastoma models.

July 31, 2026
8.0

CLINICAL

Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China

A secondary analysis of a randomized controlled trial indicates that mobile app-delivered Acceptance and Commitment Therapy significantly improves PTSD symptoms through mediating components of psychological flexibility.

digital therapeutics·Mobile·July 31, 2026
8.0

CLINICAL

DNA polymerase theta emerges as a promising target for cancer therapy

DNA polymerase theta (Polθ) is overexpressed in many cancers and is essential for microhomology-mediated end joining, making it a novel therapeutic target.

DNA·July 31, 2026
8.0

CLINICAL

Novel Rh-catalysed method yields potent antitumor phenanthridinone derivatives

A series of phenanthridinone derivatives were synthesized, with compound 3a showing potent TDP1 inhibitory activity and compound 3c demonstrating strong TOP1 inhibition and antitumor efficacy in vivo.

Novel·July 31, 2026
8.0

CLINICAL

Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated

The PANOVA-3 trial shows that Tumor Treating Fields combined with gemcitabine and nab-paclitaxel improves overall survival and progression-free survival in locally advanced pancreatic cancer patients.

gemcitabine·July 31, 2026
8.0

CLINICAL

Study on Predicting Sudden Cardiac Death Risk in Patients with Moderate LVEF

The study aims to identify markers that predict the risk of sudden cardiac death in patients with moderate left ventricular ejection fraction (LVEF) post-myocardial infarction.

Study·July 30, 2026
8.0

CLINICAL

Sodium Bicarbonate Shows Promise in Severe Metabolic Acidosis with Acute Kidney Injury

A recent trial indicates that sodium bicarbonate infusion may improve survival rates in patients with severe metabolic acidosis and acute kidney injury.

Sodium·July 29, 2026
8.0

CLINICAL

MyeloMATCH Trial Compares Venetoclax Combinations in Intermediate Risk AML

The MyeloMATCH trial is evaluating the efficacy of venetoclax in combination with standard therapies for younger patients with intermediate risk AML.

cytarabine·July 29, 2026
8.0

CLINICAL

14-3-3 Proteins Linked to Therapy Resistance in Digestive Cancers

The review identifies specific 14-3-3-client modules that contribute to therapy resistance in gastric, colorectal, pancreatic, and hepatobiliary cancers.

July 29, 2026
8.0

CLINICAL

Nanovaccines Show Superior Efficacy Over Ampicillin in Preventing Neonatal Listeriosis

Nanovaccines demonstrated greater efficacy than ampicillin in preventing neonatal listeriosis in a mouse model.

Ampicillin·July 26, 2026
8.0

CLINICAL

Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation

Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.

PD-L1·Compound·July 26, 2026
8.0

CLINICAL

H. pylori variants linked to Wnt/β-catenin signaling in stomach adenocarcinoma progression

Variants of H. pylori HtrA and CagA influence Wnt/β-catenin signaling, impacting stomach adenocarcinoma progression.

H·July 26, 2026
8.0

CLINICAL

Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer

Astellas Pharma is conducting a double-blind study to evaluate ASP2138 in combination with chemotherapy and pembrolizumab for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancer.

Astellas Pharma·ASP2138·July 25, 2026
8.0

CLINICAL

NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer

The National Cancer Institute is testing B7-H3 CAR T cell therapy in patients with refractory small cell lung cancer and extrapulmonary neuroendocrine cancer.

NCI·July 25, 2026
8.0

CLINICAL

Zanubrutinib Plus Anti-CD20 Shows Promise in R/R Follicular and Marginal Zone Lymphoma Study

A study is underway comparing zanubrutinib plus obinutuzumab to lenalidomide plus rituximab in R/R follicular lymphoma and marginal zone lymphoma.

zanubrutinib·July 25, 2026
8.0

CLINICAL

New Trial for Pediatric B-cell ALL Aims to Improve Survival Rates

The CCCG-ALL-2025 trial is designed to enhance event-free survival and overall survival in children with intermediate- and high-risk B-cell ALL.

Blinatumomab·July 25, 2026
8.0

CLINICAL

Pola-R-CHP shows promise in treating CD5-positive DLBCL, predicts patient outcomes

Interim PET response of Pola-R-CHP predicts outcomes in untreated CD5-positive DLBCL patients.

July 24, 2026
8.0

CLINICAL

Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT

The COPE-A treatment showed significantly greater reductions in PTSD symptom severity compared to supportive counseling at 4 months, with effects maintained at 12 months.

COPE-A·Efficacy·July 23, 2026
8.0

STRATEGY

VIVACITY-MG3 Study Reveals High Healthcare Costs in Generalized Myasthenia Gravis Patients Treated with Nipocalimab

The VIVACITY-MG3 study highlights significant healthcare resource utilization and economic burden in adults with generalized myasthenia gravis treated with nipocalimab.

Nipocalimab·July 22, 2026
8.0

CLINICAL

Trichodermin shows potent anti-glioblastoma effects, enhancing temozolomide efficacy

Trichodermin exhibits significant anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, while also enhancing the efficacy of temozolomide.

Trichodermin·July 22, 2026
8.0

CLINICAL

Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog

A clinical trial is evaluating the efficacy of ketamine in treating Long COVID symptoms, particularly fatigue and cognitive issues.

ketamine·July 21, 2026
8.0

CLINICAL

Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease

Merck is conducting a clinical trial to evaluate the efficacy and safety of MK-2214 in slowing tau protein accumulation in early Alzheimer's disease patients.

Merck·July 20, 2026
8.0

CLINICAL

University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses

The Opioid Rapid Response System (ORRS) project aims to train citizens in naloxone administration to reduce opioid overdose deaths.

University·July 20, 2026

Showing 1–25 of 50 records

Page 1 of 2